We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...

Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.

Tuesday’s 10 Worst Performers. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands ...

Key Takeaways The S&P 500 edged 0.2% higher on Tuesday, March 25, 2025, despite a report showing that consumer confidence ...

Burning Rock Biotech Limited’s BNR share price has dipped by 12.36%, which has investors questioning if this is right time to ...

The excitement late last year over U.S. President Donald Trump's election victory and prospects for a subsequent flurry of mergers and acquisition deals have quickly faded, they say ...

Kneat's SaaS model automates validation processes in pharma and biotech, reducing errors and ensuring compliance. Learn why ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 7.2% ...

Merck (NYSE:MRK) stock in focus as the company partners with Jiangsu Hengrui in a $2B deal for heart disease therapy HRS-5346 ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...